Cardiovascular (CV) safety of 400 and 800 mg/day of celecoxib for colorectal adenomas at 2.8–3.1 years*
| Outcome | Comparisons | Event rates | RRI (95% CI) | NNH (CI) |
|---|---|---|---|---|
| *MI = myocardial infarction. Other abbreviations defined in glossary; RRI, NNH, and CI calculated from hazard ratios in article. †Primary composite endpoint. | ||||
| CV death, non-fatal MI, stroke, or heart failure† | Celecoxib 800 v placebo | 3.4% v 1.0% | 236% (40 to 654) | 43 (16 to 252) |
| Celecoxib 400 v placebo | 2.3% v 1.0% | 129% (−10 to 438) | Not significant | |